Kymera Therapeutics (KYMR.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec10

JPMorgan Raises Kymera Therapeutics Target Price to $125

16:23

Kymera Therapeutics Inc expands its public offering to $602 million

04:31

Dec9

UBS Analyst Deyan Maintains Buy Rating on Kymera Therapeutics

12:17

Dec8

Kymera Therapeutics CEO Nello Mainolfi Sells $8.9 Million Worth of Company Stock

23:16

Kymera Therapeutics Inc's CMO Reports Sale of Common Stock

23:09

Kymera Therapeutics Releases Progress on Oral Immune Drugs

14:08

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 2.764 M, Net Income -82.18 M, EPS -0.9412

Aug11

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 11.48 M, Net Income -76.61 M, EPS -0.9523

May9

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 22.1 M, Net Income -65.58 M, EPS -0.8182

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More